HER2 amplification in Uterine carcinosarcoma after tamoxifen therapy: a case report

J Obstet Gynaecol. 2023 Dec;43(1):2125301. doi: 10.1080/01443615.2022.2125301. Epub 2022 Sep 23.

Authors

Fuqiang Zheng¹, Xiaocai Tian¹

Affiliation

¹ Department of Oncology, First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, China.

PMID: 36149352
DOI: 10.1080/01443615.2022.2125301

No abstract available

Keywords: Gynaecological oncology; HER-2; Uterine carcinosarcoma; next generation sequencing; tamoxifen.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Carcinosarcoma* / drug therapy
Carcinosarcoma* / genetics
Female
Humans
Tamoxifen / adverse effects
Uterine Neoplasms* / drug therapy
Uterine Neoplasms* / genetics

Substances

Tamoxifen